Reply To: Traders Market Weekly: Inflation and Bank Run Charades

#57708
Truman
Participant

Ascendis Pharma (ASND 82.10, +12.14, +17.4%): FDA issues complete response letter for TransCon PTH in hypoparathyroidism; no new preclinical studies, or Phase 3 clinical trials to evaluate safety or efficacy, were requested in the letter